ANCA-associated vasculitis and atypical hemolytic uremic syndrome in a patient with DGKE mutation
|
01.01.2018 |
Bulanov N.
Kozlovskaya N.
Moiseev S.
Novikov P.
Shchegoleva E.
Meshkov A.
Kuznetsova E.
Bobrova L.
|
Nephrology and Dialysis |
|
0 |
Ссылка
© 2018 S. Karger AG.All right reserved. We present a clinical case of a 34 years old female patient who simultaneously developed two rare conditions: microscopic polyangiitis and atypical hemolytic uremic syndrome (aHUS) associated with a polymorphism in diacylglycerol kinase-ε gene (DGKE), which seems to be the first case of aHUS associated with DGKE mutation in an adult patient. We suggest that the patient experienced chronic subclinical course of thrombotic microangiopathy (TMA) since adolescence, because persistent proteinuria and slowly progressive chronic kidney disease were first found when she was at the age of 13. She developed ANCA-associated vasculitis at the age of 34 with dialysis-dependent renal failure and alveolar hemorrhage that were accompanied by an acute episode of TMA. Treatment with high-dose of corticosteroids, cyclophosphamide and plasmapheresis was initiated. Alveolar hemorrhage have been resolved. However, severe hypertension, hemolytic anemia and thrombocytopenia persisted despite treatment. Plasma resistance was considered to be an indication for treatment with eculizumab, which proved to be beneficial. However, kidney function did not recover. Possible interactions between complement system, DGKE and their possible role in the pathogenesis of TMA are discussed.
Читать
тезис
|
Prospects for the treatment of preeclampsia
|
01.01.2018 |
Sidorova I.
Nikitina N.
|
Akusherstvo i Ginekologiya (Russian Federation) |
|
0 |
Ссылка
© Bionika Media Ltd. The paper presents current generalized data on the immunological aspects of preeclampsia development and progression and emphasizes the role of immunological maladaptation of the mother to pregnancy with the participation of key factors of the immune system in response to the formation of a semi-allogenic fetus and placenta. The results of recent studies allow us to take a fresh look at therapeutic approaches to managing patients with preeclampsia, by taking into account targeted exposure methods against the most important component of its pathogenesis, in particular to prevent excessive activation of the complement system.
Читать
тезис
|
Ocular thrombotic microangiopathy in atypical hemolytic-uremic syndrome (a clinical case study)
|
01.01.2018 |
Smirnova T.
Sheludchenko V.
Kozlovskaya N.
Kazaryan E.
Andzhelova D.
Sherstneva L.
Velieva I.
Kuchieva A.
Akaeva M.
|
Vestnik oftalmologii |
|
0 |
Ссылка
The article presents a clinical observation of ocular thrombotic microangiopathy in atypical hemolytic-uremic syndrome - a rare genetic disease characterized by systemic thrombosis caused by uncontrolled activation of alternative complement pathway. A typical manifestation of this ocular lesion in this disease is bilateral Purtscher-like retinopathy. Timely diagnostics of atypical hemolytic-uremic syndrome, including ophthalmologic examination, determines the early start of a highly effective pathogenetic therapy with complement inhibitor eculizumab.
Читать
тезис
|
Atypical hemolytic-uremic syndrome as one of the causes of acute kidney injury in pregnant women
|
01.01.2018 |
Kozlovskaya N.
Korotchaeva Y.
Shifman E.
Bobrova L.
|
Terapevticheskii Arkhiv |
|
0 |
Ссылка
© 2018 Media Sphera Publishing Group. All rights reserved. Obstetric atypical hemolytic uremic syndrome (aHUS) is one of the reasons for the development of acute kidney injury (AKI) and can determine the prognosis of both mother and child. Aim. Analysis of clinical manifestations, course and outcomes of obstetric aHUS. Materials and methods. 45 patients with aHUS development during pregnancy or immediately after childbirth were observed between 2011 and 2017, age from 16 to 42 years. Results and discussion. All patients had AKI (serum creatinine 521,5±388,0 μmol/l, oliguria or anuria that required initiation of hemodialysis). 93.3% pts had extrarenal manifestations of TMA with the development of multiple organ failure (MOF). The mean number of damage organs was 3,7±1,2. In all patients, the development of aHUS was preceded by obstetric complications, surgery, infection, etc. In the outcome: 53.4% women showed complete recovery of renal function, 11.1% developed CKD 4-5 stages, 35.5% had dialysis-dependent end-stage renal failure (ESDR). Maternal mortality was 23.9%. Perinatal mortality was 32.6%. The early start of eculizumab treatment (within 1-2 weeks from the onset of aHUS), compared with therapy start after 3 weeks, increased the chances of favorable outcome for mother in 5.33 times, and the chances for normalization of renal function in 48.7 times. Conclusion. Obstetric aHUS is characterized by the development of AKI in 100% of cases. In most patients, the obstetric aHUS occurs with the development of MOF. Timely diagnosis of aHUS and immediate treatment by eculizumab allows not only to save the life of patients, but also completely restore their health.
Читать
тезис
|
Effective treatment due to misconception in the diagnosis
|
01.01.2018 |
Korotchaeva Y.
Kozlovskaya N.
Shifman E.
Kuzhuget N.
Kara-Sal S.
Oorzhak O.
Badarchy M.
|
Nephrology and Dialysis |
|
0 |
Ссылка
© 2018 S. Karger AG.All right reserved. The development of thrombotic microangiopathy (TMA) during pregnancy and in postpartum period requires differential diagnosis between classical obstetric TMA (preeclampsia and HELLP-syndrome) and TMA, for which pregnancy can become a trigger of atypical hemolytic-uremic syndrome (аHUS), thrombotic thrombocytopenic purpura (TTP), obstetric sepsis with DIC-syndrome and catastrophic antiphospholipid syndrome (CAPS) in order to determine treatment strategy. Complement blocking treatment with eculizumab requires aHUS diagnosis, in the pathogenesis of which the main role is played by the uncontrolled activation of the alternative complement pathway. Complement dysregulation occurs in TMAs different from primary aHUS. Short treatment with eculizumab can result in a rapid improvement of patients with secondary aHUS in whom TMA has persisted and renal function worsened despite treatment of the TMA-inducing condition. This observation demonstrates the first experience of successful postpartum catastrophic antiphospholipid syndrome (CAPS) treatment with complement-blocking drug ekulizumab in Russia. Underestimation of the importance of detected laboratory changes and information about a burdened obstetric anamnesis led to the mistaken diagnosis of atypical HUS, which served as the basis for the ekulizumab prescription, without a doubt, saved the patient's life. The role of the complement activation in the pathogenesis of CAPS is discussed. A conclusion is made that the use of complement-blocking therapy in combination with anticoagulants primarily is advised in the obstetric CAPS patients.
Читать
тезис
|